+34 679 490 537info@nanbiosis.com

U19. Animal Modelling Unit

JUMISC

U19. Animal Modelling Unit

Order request

Description

The Unit 19 is responsible for conducting regulatory preclinical studies for the pharmaceutical industry and interested companies. Among the studies that can be carried out are: in vivo toxicity studies, local and systemic tolerance and efficacy studies. Pharmacokinetic studies,  dosage studies of test products and biocompatibility studies of new drugs and medical devices are also performed. All these safety studies are carried out using small and large animal models for the different organic systems, also including animal models of different pathologies.This Unit has a clinical analysis laboratory that performs a wide variety of analysis: (biochemistry, hematology, coagulation, urine analysis, blood gas analysis, different biomarkers, hormones, allergens) in various animal species (rat, mouse, rabbit, pig, sheep, dog, and cat). Specific methodologies are used in each animal species, having all techniques validated according to their physiological and pathological identity.

This Unit has a clinical analysis laboratory that performs a wide variety of analysis (biochemistry, hematology, coagulation, urine analysis, blood gas analysis, different biomarkers, hormones, allergens) in various animal species, such as rat, mouse, rabbit, pig, sheep, dog, and cat.

It also has a formulation laboratory equipped to formulate, reconstitute and guarantee the correct storage of the test products used in these studies.

Both laboratories are certified with ISO-9001 and Good Laboratory Practices (GLP), strict quality standards that allow the production of high-precision results

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017 Partner
PICCOLO-732111 Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support European Commission-H2020 H2020-ICT-2016-1 Partner
0624_2IQBIONEURO_6_E Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases European Union Interreg : European Territorial Co-operation POCTEP Interreg España-Portugal Partner

Other projects

Ref Title Funding Organism Unit Role
MAT2013-43299-R MACROPOROSE STRUCTURES ASSOCIATED WITH GROWTH FACTORS FOR THE RECONSTRUCTION OF OSTEOUS DEFECTS AND OSTEOPOROTIC BONE DEFECTS MINISTERIO DE ECONOMÍA Y COMPETITIVIDAD Working package